Abbott Laboratories Q4 FY25: where the revenue came from and where it went
The whole income statement of Abbott Laboratories for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 20, 2026
Revenue$11.46B
+4% year over year
Gross profit$6.54B
57% margin
Operating profit$2.25B
20% margin
Net profit$1.78B
15% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 11.46 | 100% | +4% |
| Medical devices | 5.68 | 50% | +12% |
| Diagnostic products | 2.46 | 21% | −2% |
| Nutritional products | 1.94 | 17% | −9% |
| Established pharmaceutical | 1.38 | 12% | +9% |
| Cost of revenue | −4.92 | 43% | |
| Gross profit | 6.54 | 57% margin | +2pp |
| R&D | −0.74 | 6% | +0pp |
| SG&A | −3.13 | 27% | +1pp |
| Other | −0.42 | 4% | +0pp |
| Operating profit | 2.25 | 20% margin | +2pp |
| Other income, net | 0.11 | ||
| Tax | −0.58 | ||
| Net profit | 1.78 | 15% margin | −69pp |
378 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest